SEC	Form	4
-----	------	---

FORM 4	1
--------	---

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

1. Name and Address of Reporting Person [*] Mobasher Mehrdad		r	2. Issuer Name and Ticker or Trading Symbol Corvus Pharmaceuticals, Inc. [CRVS]	(Check	ionship of Reporting Perso all applicable) Director Officer (give title	10% Owner Other (specify below)	
(Last) CORVUS PHARM 863 MITTEN ROA		(Middle) INC.	3. Date of Earliest Transaction (Month/Day/Year) 01/28/2019				
(Street) BURLINGAME (City)	CA (State)	94010 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi Line) X	idual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person		
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned							

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following	(D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(1130.4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security 8. Price of Derivative Security 3. Transaction 3A. Deemed 5. Number of 6. Date Exercisable and 7. Title and Amount 9. Number of 10. 11. Nature 2 Ownership Form: Execution Date, if any Transaction Code (Instr. 8) Conversion Expiration Date (Month/Day/Year) of Securities Underlying Derivative derivative of Indirect Date (Month/Day/Year) Beneficial or Exercise Securities Securities Price of Derivative Acquired (A) or Disposed Derivative Sec (Instr. 3 and 4) Beneficially Owned Ownership (Instr. 4) (Instr. 3) (Month/Day/Year) Security (Instr. 5) Direct (D) or Indirect Security of (D) (Instr. 3, 4 and 5) Following (I) (Instr. 4) Reported Transaction(s) Amount (Instr. 4) Number Expiration Date Code v (A) (D) Exercisable Date Title of Shares Stock Option Common \$3.88 01/28/2019 А 210,000 (1) 01/28/2029 210,000 \$0.00 210,000 D (Right to Stock

Explanation of Responses:

Buy)

1. The underlying shares subject to the option vest and become exercisable as to twenty-five percent (25%) of the shares subject to the option on January 28, 2020, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

<u>/s/ Leiv Lea, as Attorney-in-</u> Fact for Mehrdad Mobasher

01/30/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.